But the investor chooses what type of management approach to invest in so, my working thesis is that long-term ENTA investors understand the risk-reward of that approach.
Taking that kind of approach, a small company should be able to validate or kill programs efficiently. Better trial design (the earlier the better) or choosing programs that can be evaluated more efficiently are a couple ways to do that. But I was mostly curious what an investor like Dew felt would have helped make NASH a more efficient program.
Market Data 
Markets 
AI
